Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Share Analysis - Growth Trends and Forecasts (2025-2032)

Market Size and Trends

The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market is estimated to be valued at USD 912.4 million in 2025 and is expected to reach USD 1.45 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.5% from 2025 to 2032. This growth is driven by increasing prevalence of autoimmune disorders, advancements in diagnostic techniques, and the rising adoption of targeted therapies, highlighting a significant opportunity for stakeholders within the healthcare sector.

Current market trends in the CIDP segment emphasize the shift towards personalized medicine and biologic treatments, which offer improved efficacy and safety profiles compared to traditional therapies. Additionally, greater awareness and early diagnosis facilitated by technological innovations are enabling better patient outcomes. Collaborative efforts between pharmaceutical companies and research institutions are further accelerating drug development, fostering a competitive landscape focused on novel therapeutic options and expanding patient access globally.

Segmental Analysis:

By Therapeutic Type: Dominance of Intravenous Immunoglobulin (IVIg) Driven by Proven Efficacy and Established Treatment Protocols

In terms of By Therapeutic Type, Intravenous Immunoglobulin (IVIg) contributes the highest share of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market owing to its well-established efficacy and favorable safety profile. IVIg has been recognized as a first-line treatment for CIDP, providing immunomodulatory effects that help reduce nerve inflammation and improve muscle strength. Its broad clinical acceptance is reinforced by extensive clinical trial data and real-world evidence supporting its ability to induce remission and maintain long-term disease stabilization. This has cemented IVIg as a preferred therapeutic option over alternatives such as corticosteroids and plasma exchange, which may offer limited tolerability or have higher risk profiles.

Additionally, the convenience of IVIg administration in both inpatient and outpatient settings, combined with its relatively rapid onset of action, drives its widespread adoption. Contrastingly, subcutaneous immunoglobulin (SCIg), though growing, still trails IVIg due to its comparatively recent introduction and limited penetration in certain geographical regions. Immunosuppressants and corticosteroids continue to play important adjunct roles but are often associated with long-term side effects that restrict their use as sole therapies. Plasma exchange, while effective, is resource-intensive and less accessible, limiting its frequency of use. Overall, IVIg's comprehensive therapeutic benefits, coupled with ongoing enhancements in formulation and delivery, strongly underpin its market dominance within the CIDP treatment landscape.

By Diagnosis Method: Electrophysiological Tests Lead Due to Diagnostic Accuracy and Clinical Utility

In terms of By Diagnosis Method, Electrophysiological Tests hold the largest share of the CIDP market, primarily because they remain the cornerstone for accurate and early diagnosis of the disease. These tests, including nerve conduction studies and electromyography, directly assess nerve function and demyelination, enabling clinicians to differentiate CIDP from other neuropathies. Their ability to objectively measure nerve conduction velocity and identify specific patterns of demyelination is critical for confirming diagnosis, grading disease severity, and guiding treatment decisions.

The non-invasive nature of electrophysiological assessment, coupled with advancements in technology that enhance diagnostic sensitivity and specificity, has increased their clinical utility across a range of healthcare settings. Although other diagnostic methods like nerve biopsy and laboratory tests serve as important supportive tools, their invasive nature or lower specificity limits their primary usage. Clinical examination complements these tests but cannot independently establish CIDP diagnosis without electrophysiological confirmation. The widespread availability of electrophysiological equipment in specialized neurology centers and growing awareness among healthcare providers further stimulate its predominant role. Continuous improvement in standardized testing protocols and integration with emerging diagnostic biomarkers will likely reinforce their leading position in CIDP diagnostics.

By End User: Hospitals Maintain Leading Role Due to Comprehensive Care Capabilities and Multidisciplinary Approach

In terms of By End User, Hospitals contribute the highest share of the CIDP market as they provide comprehensive diagnostic and therapeutic services under one roof, facilitating timely and coordinated care for patients. The complexity of CIDP management necessitates involvement of multiple specialties, including neurology, immunology, physical therapy, and sometimes rehabilitation medicine, making hospitals the preferred treatment venues. Hospitals are equipped with state-of-the-art electrophysiological diagnostic tools, infusion centers for intravenous therapies like IVIg, and capabilities for plasma exchange, which are critical for effective management of the condition.

Moreover, hospitals offer continuous monitoring and management of disease progression and treatment-related adverse effects, ensuring patient safety especially in complex cases. Specialty clinics and diagnostic laboratories, while important, often lack the integrated infrastructure to manage severe or complicated CIDP cases comprehensively. Home care settings are gaining traction for maintenance therapies, particularly subcutaneous immunoglobulin, but remain limited by challenges in oversight and emergency backup. The ability of hospitals to provide both acute and long-term care through multidisciplinary teams and advanced technological support underpins their leadership in delivering optimal CIDP patient outcomes.

Regional Insights:

Dominating Region: North America

In North America, the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market holds a dominant position due to the well-established healthcare infrastructure, high awareness levels, and advanced diagnostic capabilities. The presence of major pharmaceutical companies and biotechnology firms specializing in autoimmune and neurological disorders bolsters the market. Strong government support through funding for neurological research and favorable regulatory frameworks accelerates product approvals and accessibility. The United States notably drives this dominance with extensive clinical trials, reimbursement policies, and patient access programs. Key players such as Grifols, Octapharma, and CSL Behring maintain a robust presence, investing heavily in R&D to innovate CIDP therapies, including immunoglobulin treatments and immunomodulatory drugs.

Fastest-Growing Region: Asia Pacific

Meanwhile, the Asia Pacific exhibits the fastest growth in the CIDP market, propelled by increasing healthcare expenditures, rising awareness of rare neurological diseases, and improving diagnostic infrastructure. The expanding middle-class population and urbanization augment demand for specialized treatments. Government initiatives in countries like Japan, China, and India aim to enhance healthcare access and improve reimbursement frameworks. Moreover, the growth of local pharmaceutical industries, alongside partnerships with multinational companies, drives market expansion. Notable companies such as Takeda Pharmaceutical, Eisai, and Shire (now part of Takeda) have intensified their focus in Asia Pacific, tailoring therapies to local demand and engaging in clinical studies that support regional approval and adoption.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Outlook for Key Countries

United States

The United States remains at the forefront of the CIDP market, supported by cutting-edge clinical research institutions and advanced biopharmaceutical presence. Market leaders like Grifols and CSL Behring contribute significantly through their immunoglobulin products and innovative therapeutic pipelines. The country's strong insurance coverage and regulatory facilitation accelerate patient access to novel treatments. Ongoing clinical trials and collaborations enhance the development of more effective and safer CIDP therapies, underpinning the country's prominent position.

Germany

Germany's CIDP market benefits from a robust healthcare system characterized by efficient reimbursement policies and high-quality patient care. The presence of dominant pharmaceutical companies, including Octapharma, strengthens local production and supply of intravenous immunoglobulin (IVIG) therapies. The government's commitment to neurological health and support for research initiatives fosters a conducive environment for therapeutic advancements. Germany also serves as a strategic hub for European clinical trials and outreach activities, enhancing market penetration.

Japan

Japan's CIDP market is evolving rapidly due to increasing government initiatives targeting rare diseases and improving healthcare infrastructure. The country's aging population and high healthcare spending fuel demand for effective CIDP management solutions. Companies such as Takeda Pharmaceutical and Eisai are pivotal in driving therapeutic innovations and have established strong distribution networks. Regulatory reforms aimed at expediting the approval of orphan drugs and biologics positively influence market dynamics.

China

China's CIDP market is witnessing significant transformation supported by enhanced diagnostic capabilities and increasing patient awareness. The government's focus on expanding healthcare access and reimbursement schemes facilitates the adoption of advanced therapies. Collaborations between multinational pharmaceutical companies and local players expedite clinical development tailored to the Chinese population. Companies like CSL Behring and local manufacturers are increasingly active, driving both manufacturing and distribution improvements.

India

India's market for CIDP is burgeoning alongside improvements in healthcare infrastructure and growing access to specialized neurological care. Government efforts to strengthen drug approval processes and insurance coverage are gradually shaping a more favorable environment. Partnerships between local pharmaceutical firms and global biopharma companies contribute to increased availability of treatment options. While challenges remain in terms of affordability and awareness, ongoing educational campaigns and healthcare reforms are boosting market prospects.

Market Report Scope

Market Segmentation

Therapeutic Type Insights (Revenue, USD, 2020 - 2032)

• Intravenous Immunoglobulin (IVIg)
• Subcutaneous Immunoglobulin (SCIg)
• Corticosteroids
• Plasma Exchange
• Immunosuppressants
• Others

Diagnosis Method Insights (Revenue, USD, 2020 - 2032)

• Electrophysiological Tests
• Nerve Biopsy
• Laboratory Tests
• Clinical Examination
• Others

End User Insights (Revenue, USD, 2020 - 2032)

• Hospitals
• Specialty Clinics
• Diagnostic Laboratories
• Home Care Settings
• Others

Regional Insights (Revenue, USD, 2020 - 2032)

• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa

Key Players Insights

• Grifols
• CSL Behring
• Octapharma AG
• Takeda Pharmaceutical Company Ltd.
• Pfizer Inc.
• Bio Products Laboratory (BPL)
• Kedrion Biopharma
• LFB Group
• Baxter International Inc.
• Becton Dickinson and Company
• Sanofi